YOLFTbeta
68

Shanghai Serum Bio-Technology Co. Ltd. A

688163 · SHG · Healthcare / Biotechnology

29.86CNY-1.17 (-3.77%)

Price History

Full chart

Market Stats

Previous Close31.03
Open30.95
Day Range29.57 – 31.60
52-Week Range20.98 – 52.70
Volume651.81K
Market Cap4.33B
P/E (TTM)78.43
Forward P/E0.00
EPS0.51
Dividend Yield0.95%
Beta0.61
50-Day Avg33.77
200-Day Avg32.16

About

Shanghai Serum Bio-Technology Co., Ltd. engages in research, development, production, operation, and sales of antitoxin and antivenom serum products for biotoxins and biosafety in China. It offers equine anti-tetanus immunoglobulin, antivenom, and anti-rabies serum products. The company also engaged in the collection and sale of animal immune plasma. The company was founded in 1999 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Tiejiong Fan
  • Employees336
  • HeadquartersNo. 1288, Huaqing Road, Shanghai, China, 201707, China
  • Websitehttps://www.serum-china.com.cn

Leadership

  • Mr. Tiejiong FanGM & Director · b. 1985
  • Mr. Liangjun PengDeputy GM, Core Technical Personnel & Director · b. 1961
  • Ms. Qiong ChengDeputy GM, Board Secretary & Director · b. 1976
  • Mr. Zhiping ZhangAssistant to GM & Core Technical Personnel · b. 1967
  • Mr. Hao ZhangGeneral Manager Assistant · b. 1971
  • Mr. Jin Bao LiuFinancial Director · b. 1977
  • Binsheng ChenAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue188.10M185.56M208.69M174.22M190.14M194.92M196.21M
Growth (%)--1.35%+12.47%-16.52%+9.14%+2.51%+0.66%
Cost of Revenue25.96M30.56M34.06M28.28M46.19M42.77M42.93M
Gross Profit162.14M155.00M174.64M145.94M143.96M152.15M153.28M
Gross Margin86.20%83.53%83.68%83.77%75.71%78.06%78.12%
Operating Expense76.78M70.87M83.40M85.30M105.96M98.76M98.42M
Operating Income85.36M84.14M91.23M60.65M37.99M53.39M54.86M
Operating Margin45.38%45.34%43.72%34.81%19.98%27.39%27.96%
EBITDA96.05M97.91M103.62M89.62M63.22M71.10M83.68M
EBITDA Margin51.07%52.77%49.65%51.44%33.25%36.48%42.65%
Net Income65.76M63.17M76.48M64.20M38.77M44.29M51.79M
Net Income Margin34.96%34.04%36.65%36.85%20.39%22.72%26.39%
R&D19.23M22.52M25.76M15.46M30.41M23.84M19.51M
R&D as % of Total Revenue10.22%12.13%12.34%8.87%15.99%12.23%9.94%
Interest Expense--710.56K680.46K648.26K430.19K179.66K
Interest Expense % of Total Revenue--0.34%0.39%0.34%0.22%0.09%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets365.11M326.29M402.89M1.17B1.13B1.12B1.16B
Total Liabilities28.17M33.15M33.26M44.86M42.63M24.53M44.55M
Total Equity336.94M293.15M369.63M1.12B1.09B1.10B1.11B
Cash131.72M118.24M115.88M515.73M150.92M182.11M33.28M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow81.85M98.35M92.29M67.91M32.82M50.25M60.53M
Capital Expenditure25.12M17.92M27.61M26.46M28.67M59.37M59.61M
Free Cash Flow56.73M80.43M64.68M41.46M4.15M-9.12M925.47K
Dividends Paid3.59M105.51M-97.39M81.16M34.63M34.63M
FCF to OCF69.31%81.78%70.09%61.04%12.63%-18.14%1.53%
Dividend Paid to FCF6.33%131.18%-234.92%1957.89%-379.88%3741.56%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----
EPS Actual0.030.240.300.010.03
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap4.33B
Enterprise Value3.40B
Trailing P/E78.43
Forward P/E0.00
Price / Sales21.69
Price / Book3.70
EPS0.51
Book Value10.35
Revenue (TTM)199.60M
Gross Profit (TTM)153.17M
EBITDA75.45M
Profit Margin27.29%
Operating Margin47.04%
Return on Equity4.89%
Return on Assets2.96%
Shares Outstanding108.22M
Shares Float43.59M
Beta0.61
Dividend Yield0.95%
Dividend Rate0.38
Payout Ratio74.51%

Dividends

20262×
0.12Sep 15, 20260.26May 29, 2026
20252×
0.12Sep 26, 20250.20Jun 5, 2025
20242×
0.12Sep 12, 20240.20Jun 3, 2024
20231×
0.75May 29, 2023
20221×
0.90Jun 7, 2022